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The effect of ex-vivo rotenone intoxication on dopamine re-uptake of LRRK2-R1441G mutant 
mouse
S Lu, HF Liu, PWL Ho, JWM Ho, DHF So, ZHM Tse, MHW Kung, DB Ramsden, SL Ho
Division of Neurology, Department of Medicine, The University of Hong Kong, Hong Kong
introduction: Mutations in LRRK2 are strongly associated with Parkinson’s disease, and R1441G is the second 
most common mutation of LRRK2. In order to develop a mouse model for Parkinson’s disease, we have 
generated a knock-in mouse carrying this mutation. However, the mutant mice remain healthy and do 
not demonstrate any behavioural or histological abnormalities until 18 months old. Since an important 
neurochemical defect in Parkinson’s disease is decreased dopamine content in the striatum, and both genetic 
background and environmental stress make contribution to the disease progression, we investigated the effect 
of LRRK2-R1441G mutation and ex-vivo rotenone treatment on the ability of dopamine re-uptake.
Methods: Synaptosomes were isolated from mouse striatum and incubated with 3H-labelled dopamine with or 
without low-dose rotenone pre-treatment, and the radioactivity of synaptosomes was measured to assess the 
ability of dopamine re-uptake by dopaminergic neurons. Wild type and LRRK2R1441G/R1441G mutant mice at both 3 
months and 18 months old were compared.
Results: There was no significant difference in the ability of dopamine re-uptake between wild type and mutant 
mice in either young (3 months old) or aged (18 months old) groups without rotenone treatment. However, 
dopamine re-uptake is significantly compromised in the mutant mice at 3 months old under rotenone 
treatment.
Conclusions: LRRK2-R1441G alone may not be sufficient to affect dopamine transmission even in aged mice, 
but the synergetic effect of LRRK2 mutation and rotenone stimulus can lead to impaired dopamine uptake. 
Therefore, this study implies the importance of interaction between genetic and environmental factors in 
Parkinson’s disease.
Acknowledgements: This research is supported by the Donation Fund for Neurology Research (SL Ho) and Seed Funding for 
Basic Research, Committee on Research and Conference Grants (HKU200901159008; PWL Ho).
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A pilot study on the efficacy and safety of Prismocitrate 18/0 replacement solution in  
continuous venovenous haemodiafiltration (CVVHDF)
MMS Lui, NYY Leung, MF Lam, WM Chan
Intensive Care Unit, Queen Mary Hospital, The University of Hong Kong, Hong Kong
introduction: Regional citrate anticoagulation is efficacious for prolonging filter function, and confers less risk of 
bleeding and mortality compared to systemic anticoagulation. However, technical complexity, risks of sodium 
disturbance and citrate toxicity related to older citrate formulation limit its widespread use. Primocitrate 18/0 
(Gambro), a new formulation of citrate with modified sodium content, could potentially ameliorate these 
side-effects. We aimed to develop a feasible protocol using this solution coupled with calcium-free dialysate 
(Prism0cal B22) for CVVHDF, and to determine its safety and efficacy for local critical care setting. 
Methods: Asian medical patients admitted to the adult Intensive Care Unit (AICU) of Queen Mary Hospital who 
are indicated for continuous renal replacement therapy, without a history of advanced cirrhosis, or shock on 
high dose vasopressor, are recruited. The protocol adopts fixed flow rates of blood and Primocitrate 18/0 as pre-
dilution at 120 mL/min and 1000 mL/min, respectively. Dialysate (Prism0cal B22) flow rate was adjusted according 
to body weight to achieve the ultrafiltration dose of 30-35 mL/kg/hour. CVVHDF is performed using Prismaflex® 
machine with high-flux filter (ST100, Gambro). Pre-filter and post-filter calcium levels target between 0.3 and 
0.5 mmol/L. Calcium was replaced systemically via a separate central venous access. Systemic total calcium to 
ionised calcium ratio (target <2.5) was monitored for potential citrate toxicity.
Results: Fifteen eligible subjects (10 males, 5 females; age 49-85 years) were recruited so far. All of them fulfilled 
the AKIN definition of acute kidney injury and two of them were diagnosed metformin-associated-lactic-acidosis. 
Nine of them completed the CVVHDF therapy without filter clotting, and CVVHDF therapy last 12 to 72 hours. 
No electrolytes disturbance, citrate toxicity, or bleeding episode was reported after starting on the protocol. 
Filter clotting was reported in three subjects, after CVVHDF for 26, 38, 53 hours. Among the three subjects with 
filter clotted, catheter malfunction requiring A-V swapping was reported in two, which was believed to be a 
major reason predisposing to clotting of filter. The remaining subject had venous thrombosis elsewhere and 
required investigations for systemic thrombotic tendency. Three subjects were withdrawn from the study after 
CVVHDF for 5, 12 and 21 hours, subsequent to clinical deterioration with the development of contra-indications 
for citrate infusion. All subjects achieved pre-filter and post-filter calcium level within the targeted range. 
Systemic ionised calcium level was maintained within safe range (1.0-1.2 mmol/L) using the current protocol. 
Conclusion: The current CVVHDF protocol using Prismocitrate 18/0 as replacement solution is feasible and no 
adverse events were reported so far. Safety profile is to be observed further upon ongoing recruitment. 
Acknowledgement: The author would like to acknowledge the support from Gambro and contribution to the work from the 
ICU team.
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